ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 176 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2016. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $7,606,007 | +148.9% | 185,061 | +182.8% | 0.00% | +100.0% |
| Q1 2024 | $3,055,300 | -47.1% | 65,438 | -45.8% | 0.00% | -50.0% |
| Q4 2023 | $5,772,591 | +446.1% | 120,715 | +307.1% | 0.00% | – |
| Q3 2023 | $1,057,022 | -70.5% | 29,650 | -61.8% | 0.00% | -100.0% |
| Q2 2023 | $3,580,933 | +210.4% | 77,627 | +169.8% | 0.00% | – |
| Q1 2023 | $1,153,797 | -19.3% | 28,773 | -6.8% | 0.00% | -100.0% |
| Q4 2022 | $1,429,883 | -1.4% | 30,863 | -11.8% | 0.00% | 0.0% |
| Q3 2022 | $1,450,000 | +118.4% | 35,000 | +214.2% | 0.00% | – |
| Q2 2022 | $664,000 | -78.4% | 11,139 | -73.7% | 0.00% | – |
| Q1 2022 | $3,071,000 | -52.0% | 42,291 | -44.4% | 0.00% | -100.0% |
| Q4 2021 | $6,392,000 | -22.6% | 76,008 | -17.0% | 0.00% | -33.3% |
| Q3 2021 | $8,261,000 | +1.1% | 91,601 | +6.9% | 0.00% | 0.0% |
| Q2 2021 | $8,173,000 | +247.2% | 85,723 | +314.7% | 0.00% | +200.0% |
| Q1 2021 | $2,354,000 | -67.7% | 20,673 | -60.7% | 0.00% | -66.7% |
| Q4 2020 | $7,290,000 | +115.8% | 52,664 | +28.1% | 0.00% | +50.0% |
| Q3 2020 | $3,378,000 | +8.5% | 41,097 | +3.3% | 0.00% | 0.0% |
| Q2 2020 | $3,112,000 | +270.9% | 39,788 | +102.5% | 0.00% | +100.0% |
| Q4 2019 | $839,000 | +89.0% | 19,651 | +89.2% | 0.00% | 0.0% |
| Q3 2019 | $444,000 | -77.3% | 10,385 | -59.4% | 0.00% | -75.0% |
| Q3 2018 | $1,954,000 | +476.4% | 25,602 | +284.9% | 0.00% | +300.0% |
| Q1 2018 | $339,000 | -17.1% | 6,652 | -24.6% | 0.00% | 0.0% |
| Q4 2017 | $409,000 | +9.9% | 8,821 | +26.1% | 0.00% | 0.0% |
| Q3 2017 | $372,000 | -34.5% | 6,993 | -12.6% | 0.00% | -66.7% |
| Q3 2016 | $568,000 | +37.9% | 8,000 | +23.0% | 0.00% | +50.0% |
| Q1 2016 | $412,000 | -38.6% | 6,505 | +8.8% | 0.00% | -50.0% |
| Q4 2015 | $671,000 | -20.2% | 5,981 | -27.2% | 0.00% | -20.0% |
| Q2 2015 | $841,000 | – | 8,211 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
| Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
| Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
| AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
| EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
| FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
| HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
| Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |